文献库搜索 | GeneLibs

主页文献库搜索

搜索排行

TP53 BRCA1 CRISPR single-cell cancer

Wang(W),Yang(C),Zhao(J),Cheng(X),Chen(T),Y... Arch Biochem Biophys 2025-12-00

...BRCA1, KRAS, MSH6, SMARCA4, SRC, and TSC1) exhibited significant correlations with immune infiltration (CD8+ T cells, Tr...

Sato(Y),Fujii(Y),Nakamura(M),Tanai(C),Yama... IJU Case Rep 2025-11-00

...BRCA1/2 gene. For other HRR-related genes, there is insufficient evidence to determine whether PARP inhibitors are effec...

Butz(H),Patócs(A) Magy Onkol 2025-09-24

...BRCA1/2 variants, along with related screening, prevention, and management recommendations, including risk-reducing surg...

Zhang(J),Wang(X),Xue(Y) Case Rep Oncol 2025-00-00

...BRCA1 mutations, or those at high risk of developing skeletal-related events may benefit from denosumab over zoledronic ...

Lopez(BS) Oncogene 2025-11-00

...BRCA1 or BRCA2) in cancer result in the absence of RAD51 on damaged DNA, leaving access to alternative exclusively mutag...

Son(Y),Ryu(JY) Int J Mol Sci 2025-09-29

PARP inhibitors exploit synthetic lethality in BRCA1/2-mutated ovarian cancers but are limited by emerging therapeutic r...

Mochirian(P),Papp(R),Mathieu(MC),Ferraro(G... J Med Chem 2025-09-25

...BRCA1 or BRCA2 mutations. Here, we describe the discovery and preclinical development of RP-2119, a selective, potent, a...

Özer(L),Aktuna(S),Ünsal(E) Eur J Breast Health 2025-09-25

...BRCA1/BRCA2 sequencing data and reclassified the BRCA1/2 variants of unknown significance (VUS) in Turkish patients with...

De Leonardis(F),Di Noia(MA),Turchiano(A),M... Sci Rep 2025-09-24

...BRCA1/2 mutations contribute to tumor initiation through early reprogramming of both stromal and epithelial compartments...

Yuan(H),Wang(T),Yao(H),Wu(L),Li(N) J Ovarian Res 2025-09-26

...BRCA1/2 gene mutations. The median duration of PARPi1 and PARPi2 in the entire cohort was 11.2 months (range: 2.0-30.4 m...

上一页 116 117 118 119 120 121 122 123 124 下一页第 120 / 共 1000 页